AI assistant
Spyre Therapeutics, Inc. — Director's Dealing 2021
Feb 9, 2021
32226_dirs_2021-02-08_f7441d1c-0184-4c6e-9458-52d27cf165a2.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Aeglea BioTherapeutics, Inc. (AGLE)
CIK: 0001636282
Period of Report: 2021-02-02
Reporting Person: Weber Steven (VP, Controller&Princ Acctg Off)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 17652 | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Employee Stock Option (right to buy) | $3.465 | 2025-03-31 | Common Stock (3394) | Direct | |
| Employee Stock Option (right to buy) | $3.465 | 2025-03-31 | Common Stock (12428) | Direct | |
| Employee Stock Option (right to buy) | $6.195 | 2025-05-27 | Common Stock (2290) | Direct | |
| Employee Stock Option (right to buy) | $8.03 | 2027-03-19 | Common Stock (22500) | Direct | |
| Employee Stock Option (right to buy) | $3.10 | 2027-08-21 | Common Stock (12000) | Direct | |
| Employee Stock Option (right to buy) | $8.98 | 2028-08-06 | Common Stock (15000) | Direct | |
| Employee Stock Option (right to buy) | $8.36 | 2029-02-27 | Common Stock (15000) | Direct | |
| Employee Stock Option (right to buy) | $6.31 | 2028-02-19 | Common Stock (14000) | Direct | |
| Employee Stock Option (right to buy) | $8.15 | 2030-02-13 | Common Stock (17000) | Direct |
Footnotes
F1: The options are fully vested.
F2: The stock option vests and becomes exercisable in 48 equal monthly installments beginning on April 20, 2017, until such time as the option is 100% vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
F3: The stock option vests and becomes exercisable in 48 equal monthly installments beginning on September 7, 2018, until such time as the option is 100% vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
F4: The stock option vests and becomes exercisable in 48 equal monthly installments beginning on March 31, 2019, until such time as the option is 100% vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
F5: The stock option vests and becomes exercisable in 48 equal monthly installments beginning on March 20, 2018, until such time as the option is 100% vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
F6: The stock option vests and becomes exercisable in 48 equal monthly installments beginning on March 14, 2020, until such time as the option is 100% vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.